BioEurope Spring 2017 presentation of progress in three pipeline programs
Stockholm, 20 March 2017. Nuevolution AB (publ) (NUE.ST) will participate in BioEurope Spring in Barcelona, 20-22 March and present updates on the company’s RORgt inhibitor, RORgt agonist and BET BD1 programs. Ton Berkien, CBO, and Søren Jensby Nielsen, Director of Biology, will present positive preliminary data from two independent mouse models of Inflammatory Bowel Disease (IBD) in the RORgt inhibitor program outside its partnership with Almirall. The IBD studies showed a significant effect by ameliorating colon parameters at therapeutically relevant doses of an RORgt inhibitor.